276 related articles for article (PubMed ID: 9538140)
1. P-glycoprotein-mediated multidrug resistance is modulated by pretreatment with chemosensitizers in HCT-8 carcinoma cells in vitro.
Haberl I; Swatonek H; Schaufler K; Ulsperger E; Wenzl E; Theyer G; Hamilton G; Thalhammer T
Int J Oncol; 1998 May; 12(5):1137-42. PubMed ID: 9538140
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH.
Zacherl J; Hamilton G; Thalhammer T; Riegler M; Cosentini EP; Ellinger A; Bischof G; Schweitzer M; Teleky B; Koperna T
Cancer Chemother Pharmacol; 1994; 34(2):125-32. PubMed ID: 7910786
[TBL] [Abstract][Full Text] [Related]
3. Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15.
Uchiyama-Kokubu N; Watanabe T; Cohen D
Jpn J Cancer Res; 2001 Oct; 92(10):1116-26. PubMed ID: 11676863
[TBL] [Abstract][Full Text] [Related]
4. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
Jiang XR; Kelsey SM; Wu YL; Newland AC
Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760
[TBL] [Abstract][Full Text] [Related]
5. SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma.
Jonsson B; Nilsson K; Nygren P; Larsson R
Anticancer Drugs; 1992 Dec; 3(6):641-6. PubMed ID: 1363199
[TBL] [Abstract][Full Text] [Related]
6. Modulator activity of PSC 833 and cyclosporin-A in vincristine and doxorubicin-selected multidrug resistant murine leukemic cells.
Lopes EC; Scolnik M; Alvarez E; Hajos SE
Leuk Res; 2001 Jan; 25(1):85-93. PubMed ID: 11137565
[TBL] [Abstract][Full Text] [Related]
7. Drug binding to P-glycoprotein is inhibited in normal tissues following SDZ-PSC 833 treatment.
Jetté L; Murphy GF; Béliveau R
Int J Cancer; 1998 May; 76(5):729-37. PubMed ID: 9610733
[TBL] [Abstract][Full Text] [Related]
8. Drug resistance in multiple myeloma: cyclosporin A analogues and their metabolites as potential chemosensitizers.
Pilarski LM; Yatscoff RW; Murphy GF; Belch AR
Leukemia; 1998 Apr; 12(4):505-9. PubMed ID: 9557608
[TBL] [Abstract][Full Text] [Related]
9. Decreased uptake of cyclosporin A by P-glycoprotein (Pgp) expressing CEM leukemic cells and restoration of normal retention by Pgp blockers.
Didier A; Wenger J; Loor F
Anticancer Drugs; 1995 Oct; 6(5):669-80. PubMed ID: 8845477
[TBL] [Abstract][Full Text] [Related]
10. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines.
Theyer G; Schirmböck M; Thalhammer T; Sherwood ER; Baumgartner G; Hamilton G
J Urol; 1993 Nov; 150(5 Pt 1):1544-7. PubMed ID: 8105110
[TBL] [Abstract][Full Text] [Related]
11. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines.
van der Sandt IC; Blom-Roosemalen MC; de Boer AG; Breimer DD
Eur J Pharm Sci; 2000 Sep; 11(3):207-14. PubMed ID: 11042226
[TBL] [Abstract][Full Text] [Related]
12. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes.
Drach J; Gsur A; Hamilton G; Zhao S; Angerler J; Fiegl M; Zojer N; Raderer M; Haberl I; Andreeff M; Huber H
Blood; 1996 Sep; 88(5):1747-54. PubMed ID: 8781431
[TBL] [Abstract][Full Text] [Related]
13. Differential modulation of P-glycoprotein transport by protein kinase inhibition.
Bates SE; Lee JS; Dickstein B; Spolyar M; Fojo AT
Biochemistry; 1993 Sep; 32(35):9156-64. PubMed ID: 7690250
[TBL] [Abstract][Full Text] [Related]
14. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
15. Xenobiotic transport differences in mouse mesangial cell clones expressing mdr1 and mdr3.
Ernest S; Bello-Reuss E
Am J Physiol; 1996 Mar; 270(3 Pt 1):C910-9. PubMed ID: 8638674
[TBL] [Abstract][Full Text] [Related]
16. Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein.
Watanabe T; Uchiyama N; Roninson IB; Cohen D; Atadja P
Int J Oncol; 2000 Sep; 17(3):579-86. PubMed ID: 10938401
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein.
Kusunoki N; Takara K; Tanigawara Y; Yamauchi A; Ueda K; Komada F; Ku Y; Kuroda Y; Saitoh Y; Okumura K
Jpn J Cancer Res; 1998 Nov; 89(11):1220-8. PubMed ID: 9914792
[TBL] [Abstract][Full Text] [Related]
18. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Grey M; Borg AG; Wood P; Burgess R; Fisher A; Yin JA
Leuk Res; 1997 Sep; 21(9):867-74. PubMed ID: 9393602
[TBL] [Abstract][Full Text] [Related]
19. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo.
Watanabe T; Tsuge H; Oh-Hara T; Naito M; Tsuruo T
Acta Oncol; 1995; 34(2):235-41. PubMed ID: 7718262
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system.
Ramachandra M; Ambudkar SV; Gottesman MM; Pastan I; Hrycyna CA
Mol Biol Cell; 1996 Oct; 7(10):1485-98. PubMed ID: 8898356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
